October 31, 2017 Clinical Research/Diagn. M&A, Partnerships

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines Agreement to expand Oncomine Dx Target Test with RET fusion markers to treat non-small cell lung cancer patients CARLSBAD, Calif., Oct. 31, 2017 /PRNewswire/ — As part of its ongoing commitment to increase the utility of next-generation sequencing (NGS) in the clinic, Thermo Fisher... Read more

October 31, 2017 Clinical Research/Diagn. Product Launch

New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease

Basel, 31 October 2017 New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease Roche presents etrolizumab data in Crohn’s disease and ulcerative colitis at UEGW Data suggest etrolizumab leads to endoscopic improvement associated with early symptomatic remission in Crohn’s disease... Read more

October 30, 2017 Clinical Research/Diagn.

QIAGEN Accelerates Adoption of Molecular Testing for Life Sciences and Molecular Diagnostics Companies with Launch of Custom Solutions Business 

Trusted QIAGEN partners can now increase their speed to market by leveraging the company’s industry expertise, world-class manufacturing and thousands of product formulations Beverly, Mass., October 30, 2017 – QIAGEN today announced the launch of its Custom Solutions business, extending its commitment to providing life sciences and molecular diagnostics companies with the tools and expertise... Read more

October 27, 2017 Clinical Research/Diagn. Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis

Basel, 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS) Data demonstrates first method to automatically detect and characterise... Read more

October 27, 2017 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

October 27, 2017 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal Microscopy

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

October 25, 2017 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Shimadzu Scientific Instruments, Cure Pharmaceutical Corp and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products

Columbia, MD (October 25, 2017) — Shimadzu Scientific Instruments, the leading provider of cannabis testing instruments, announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.... Read more

October 25, 2017 Clinical Research/Diagn. Life Science Tools

BD Breaks Ground on $60 Million Expansion of Nebraska Manufacturing Facility

COLUMBUS, Neb., Oct. 25, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to break ground on a $60 million upgrade of its Columbus-East facility. The 69,000 sq. ft. expansion will transform the Columbus-East facility into... Read more

October 19, 2017 Clinical Research/Diagn. Informatics & Software Life Science Tools M&A, Partnerships

Fabric Genomics Partners to Improve Pediatric Care

October 19, 2017 06:00 AM Pacific Daylight Time ORLANDO, Fla.–(BUSINESS WIRE)–Fabric Genomics has partnered with Genomics England’s 100,000 Genomes Project, Rady Children’s Institute for Genomic Medicine (RCIGM), and The Utah Genome Project (UGP), to provide fast and accurate identification of pediatric disease-causing variants to improve the clinical care of children. Fabric Genomics’ Opal™ Clinical is the only genomic interpretation and reporting... Read more